FindTrial
Sign In

Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients

Impacts of Superselective Infarct-related Artery Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in ST Segment Elevation Myocardial Infarction (STEMI) Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01181388
Acronym
SUIT-AMI
Enrollment
200
Registered
2010-08-13
Start date
2010-04-30
Completion date
2012-10-31
Last updated
2010-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Brief summary

Superselective IRA infusion of tirofiban may improve myocardial reperfusion and reduce bleeding complications in AMI patients.

Interventions

PROCEDUREadministration of tirofiban by thrombus aspiration catheter in infarct-related artery

a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI

PROCEDUREadministration of tirofiban by guide catheter

a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI

Sponsors

Beijing Anzhen Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* STEMI patients * chest pain for less than 12hr * plan to PCI

Exclusion criteria

* LM lesion * stent thrombosis * cardiac shock * thrombocytopenia * allergy to asprin

Design outcomes

Primary

MeasureTime frameDescription
Major Adverse Cardiovascular Events6 months after PCIInfarct size, reinfarction, motality, et.al.
Major adverse cardiovascular events1 month after PCIInfarct size, reinfarction, motality, et.al.

Secondary

MeasureTime frameDescription
number of participants with bleeding events1 monthbleeding events are assessed by Thrombolysis In Myocardial Infarction(TIMI) criteria

Countries

China

Contacts

Primary ContactShaoping Wang, MD, PhD
wang_shaoping@hotmail.com+861064456995
Backup ContactYunpeng Chi, MD
chiyunpeng0711@sohu.com+861064456541

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026